Antimicrobial peptides (AMPs) are the most active area of non-GLP-1 peptide drug development. They hit pathogens — including carbapenem-resistant gram-negatives — by mechanisms small-molecule antibiotics cannot match: membrane disruption, biofilm penetration, and rapid bactericidal activity that makes resistance evolution slower.
Programs covered on this site include Peptilogics' work on prosthetic-joint biofilm, Fedora Pharmaceuticals' FPI-2119 lactivicin against gram-negative organisms, the HMD-AMP discovery platform from HLB Innovation (Nature Biomedical Engineering), and academic programs on persister-cell killing, MRSA, and Acinetobacter baumannii.
The gap is delivery and clinical economics. Most AMP candidates run into instability or selectivity ceilings before Phase 2. The ones moving fastest combine novel scaffolds with AI-driven design. See #amr and #antibiotic-resistance for resistance context.
A January 2026 Frontiers in Cellular and Infection Microbiology review synthesized the case for antimicrobial peptides (AMPs) as the most promising response to antimicrobial resistance, which is responsible for nearly 5 million deaths annually and projected to double by 2050. The review emphasizes that AMPs' rapid, multi-target mechanism — primarily physical membrane disruption — produces significantly lower incidence of resistance emergence than traditional small-molecule antibiotics. The pipeline now exceeds 150 active candidates spanning AI-designed AMPs, lysin-derived peptides, and venom-derived sequences.
A recent PubMed-indexed study reports that Mu-17 — a novel antimicrobial peptide designed using a bio-inspired approach based on scorpion AMP leucine-zipper-like motifs — showed both antimicrobial and anticancer activity with reduced toxicity. Mu-17 inhibited breast cancer cell proliferation with IC50 of 13 µM and exhibited remarkably low hemolytic activity (18% at 100 µM). The work adds to the emerging category of venom-derived peptides with dual therapeutic applications, complementing ongoing AI-driven antimicrobial peptide discovery efforts disclosed at AACR 2026 and ESCMID 2026.
A new Nature Biomedical Engineering paper introduces HMD-AMP, a protein language model-based approach that outperforms prior methods at identifying evolutionarily distant antimicrobial peptides. Applied to host and gut microbiome genomes of nine mammals, HMD-AMP revealed over 37 million predicted AMPs. Of 91 experimentally validated high-confidence sequences, 74 showed strong antibacterial activity and 48 were evolutionarily remote from known AMPs, including four with broad-spectrum activity at low toxicity.
The European Society of Clinical Microbiology & Infectious Diseases (ESCMID) Global 2026 opened today at Messe München, running April 17-21 with ~18,000 international participants. Antimicrobial resistance dominates the agenda, with presentations featuring novel antimicrobial peptides, peptide-antibody hybrids, and AI-driven AMP discovery platforms. ESCMID is the largest international clinical microbiology and infectious diseases conference worldwide.
A Nature Communications paper introduces CAMPER (Constraint-driven AMP Engineering with Ranking), a mechanistic AI framework that integrates machine learning with biophysical ranking to design membrane-targeting peptides against MRSA persisters and biofilms. The framework identified WP-CAMPER1, a 12-mer peptide that kills S. aureus MW2 at an MIC of 4 µg/mL; a 2% topical formulation reduced S. aureus burden by 2.5 log10 in a murine skin infection model.
A Nature Communications paper published April 15 reveals shared structural mechanisms between SbmA — an E. coli membrane transporter that imports antimicrobial peptides — and ABC transporters. Using cryo-electron microscopy, EPR spectroscopy, and molecular dynamics simulations, researchers demonstrated SbmA undergoes ABC-transporter-like conformational changes, informing strategies to design antibiotic-resistant-bacteria-penetrating peptide drugs.
A comprehensive review in Discover Oncology highlights antimicrobial peptides' emerging dual role as anticancer and antiviral therapeutics. AMPs selectively target cancer cell membranes through electrostatic interactions while also demonstrating antiviral activity, with their immunomodulatory properties and reduced resistance development offering advantages over conventional chemotherapy.
A study in Nature Microbiology used a generative protein language model (ProteoGPT) to discover novel antimicrobial peptides effective against multidrug-resistant bacteria. The AI-designed peptides showed comparable or superior efficacy to clinical antibiotics in mouse infection models, with reduced resistance development and no organ damage.
UC launched a clinical trial using Peptilogics' peptide-based antimicrobial agent to treat prosthetic joint infections by targeting bacterial biofilms that have resisted traditional therapies.